BIA
MCRB icon

Bell Investment Advisors’s Seres Therapeutics MCRB Stock Holding History

Bell Investment Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31
Closed -$508 – 1930
2024
Q4 		$508 Buy
+31
New +$504 ﹤0.01% 1763
2022
Q3 		– Sell
-2
Closed – – 1860
2022
Q2 		$0 Buy
+2
New +$172 ﹤0.01% 1788
2021
Q4 		$0 Hold
2
– – ﹤0.01% 1882
2021
Q3 		$0 Buy
+2
New +$391 ﹤0.01% 1787

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bell Investment Advisors's MCRB Position: Q1 2025 in Review

Bell Investment Advisors sold out of Seres Therapeutics (MCRB) in Q1 2025, closing a stake of 31 shares — an estimated $508 sold.

Bell Investment Advisors first reported a position in MCRB in Q3 2021 and held it in 4 quarters. The position peaked at $508 in Q4 2024. 63 funds tracked by Wall St. Rank hold MCRB as of Q1 2025.

  • Bell Investment Advisors reported no remaining Seres Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bell Investment Advisors sold 31 Seres Therapeutics shares in Q1 2025, an estimated $508.
  • Bell Investment Advisors first reported a position in Seres Therapeutics in Q3 2021 and held it in 4 quarters.
  • Bell Investment Advisors's Seres Therapeutics position peaked at $508 in Q4 2024.
  • 63 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2025.

Based on Bell Investment Advisors's 13F filing for Q1 2025, filed 16 May 2025.